Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation (CERS) maintains global leadership in blood safety through its INTERCEPT Blood System, a pathogen inactivation platform protecting transfusion medicine worldwide. This dedicated news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical advancements, and operational developments.
Access timely reports on FDA clearances, European CE marks, and partnerships with blood centers across 40+ countries. Track progress in platelet and plasma treatment adoption, red blood cell system trials, and international expansion efforts. Our curated news collection ensures you never miss critical updates about this biomedical innovator.
Key coverage areas include quarterly financial results analysis, peer-reviewed study publications, manufacturing capacity expansions, and strategic collaborations with global health organizations. All content is verified through primary sources including company filings and official statements.
Bookmark this page for streamlined access to CERS developments impacting transfusion safety standards. Combine real-time alerts with historical context to understand Cerus' role in combating emerging bloodborne pathogens through cutting-edge nucleic acid targeting technology.
Cerus Corporation (CERS) reported third quarter 2022 total revenue of $46.3 million, a 10% year-over-year increase, driven by $39.6 million in product revenue. Despite a 6% foreign exchange headwind, product gross profit rose to $21.9 million, with a gross margin of 55.4%. The net loss narrowed to $8.5 million or $0.05 per share. Cerus has secured a $9.1 million contract with the DoD for trauma treatment development and expects full-year product revenue guidance between $160 million and $162 million.
Cerus Corporation has been awarded a
Cerus Corporation (Nasdaq:CERS) has received approval from Health Canada to extend the storage life of platelets treated with the INTERCEPT Blood System from five days to seven days. This approval supports Cerus' partnership with Canadian Blood Services and aims to enhance the availability of pathogen-reduced platelets across Canada. The extension will allow better utilization of platelet supply, minimizing waste and safeguarding against pathogens. Canadian Blood Services manufactures approximately 115,000 platelet doses annually.
Cerus Corporation (NASDAQ: CERS) will release its third quarter 2022 financial results on November 3, 2022, after market close. A conference call and webcast will be held at 4:30 P.M. ET that day, where management will discuss financials and business outlook. The event can be accessed via the Cerus Investor Relations page. A replay will be available approximately three hours post-call until November 17, 2022. The company focuses on safeguarding the blood supply with its INTERCEPT Blood System, which is FDA approved for platelets and plasma.
Cerus Corporation (Nasdaq:CERS) reported its participation in the 2022 AABB Annual Meeting in Orlando, FL from October 1-4. This marks the conference's first in-person event since 2019. Cerus will present several abstracts highlighting the benefits of the INTERCEPT Blood System for Platelets and Cryoprecipitation. Key presentations include a plenary session on platelet safety and storage and a dedicated industry workshop. The INTERCEPT systems are pivotal for pathogen reduction in blood products and have received both CE mark and FDA approval.
Cerus Corporation (NASDAQ: CERS) acknowledges the U.S. Department of Health and Human Services' declaration of monkeypox as a national Public Health Emergency, with over 10,000 reported cases in the U.S. and 30,000 globally. The company highlights its INTERCEPT Blood System, which has been effective in inactivating a broad spectrum of pathogens, including the vaccinia virus, a close relative of monkeypox. This technology provides essential support in safeguarding the blood supply against emerging infectious diseases, ensuring blood safety and availability during outbreaks.
Cerus Corporation (Nasdaq: CERS) reported record product revenue of $41.0 million for Q2 2022, a 30% year-over-year increase, contributing to total revenue of $47.6 million, up 26% compared to the previous year. The company reiterated its full-year product revenue guidance of $160-165 million, reflecting a 22%-26% growth. Despite a net loss of $8.4 million, improved expense management led to a better financial position with cash reserves of $107 million. The INTERCEPT Blood System has surpassed 12 million treatable doses globally.
Cerus Corporation (CERS) will release its second quarter 2022 financial results on August 4, 2022, post-market. A conference call is scheduled for 4:30 PM ET to discuss the results and business outlook. The company focuses on safeguarding the global blood supply, with its INTERCEPT Blood System approved for platelets and plasma. The red blood cell system is undergoing regulatory review in Europe and clinical development in the US. A replay of the call will be available on the company's website.
Cerus Corporation (NASDAQ: CERS) announced the appointment of Dr. Hua Shan to its Board of Directors. Dr. Shan, a renowned expert in transfusion medicine with over 25 years of experience, aims to enhance Cerus' efforts in the Chinese market for its INTERCEPT Blood System. The Board Chair, Daniel Swisher, expressed confidence that Dr. Shan's extensive knowledge will positively impact Cerus' global presence and product safety initiatives. Dr. Shan previously served in key roles at prestigious institutions, including Stanford Medical Center and Johns Hopkins University.
FAQ
What is the current stock price of Cerus (CERS)?
What is the market cap of Cerus (CERS)?
